193 related articles for article (PubMed ID: 19346783)
1. [Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea].
Kim BK; Kwon SY; Lee CH; Choe WH; Choi HM; Koo HW
Korean J Hepatol; 2009 Mar; 15(1):25-41. PubMed ID: 19346783
[TBL] [Abstract][Full Text] [Related]
2. [An economic evaluation of different treatments for HBeAg-positive chronic hepatitis B in China].
Larry L; Lu XZ; Alison T
Zhonghua Gan Zang Bing Za Zhi; 2007 Jun; 15(6):431-6. PubMed ID: 17594808
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of chronic hepatitis B treatments in Taiwan.
Lacey L; Chien RN; Chuang WL; Pwu RF
J Gastroenterol Hepatol; 2008 Apr; 23(4):571-9. PubMed ID: 18397486
[TBL] [Abstract][Full Text] [Related]
4. The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore.
Lacey LF; Gane E
J Viral Hepat; 2007 Nov; 14(11):751-66. PubMed ID: 17927611
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis.
Veenstra DL; Spackman DE; Di Bisceglie A; Kowdley KV; Gish RG
Aliment Pharmacol Ther; 2008 Jun; 27(12):1240-52. PubMed ID: 18373637
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
Wu B; Li T; Chen H; Shen J
Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
[TBL] [Abstract][Full Text] [Related]
8. Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B.
Buti M; Brosa M; Casado MA; Rueda M; Esteban R
J Hepatol; 2009 Oct; 51(4):640-6. PubMed ID: 19576651
[TBL] [Abstract][Full Text] [Related]
9. A systematic review and economic evaluation of adefovir dipivoxil and pegylated interferon-alpha-2a for the treatment of chronic hepatitis B.
Takeda A; Jones J; Shepherd J; Davidson P; Price A
J Viral Hepat; 2007 Feb; 14(2):75-88. PubMed ID: 17244247
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B.
Buti M; Casado MA; Calleja JL; Salmerón J; Aguilar J; Rueda M; Esteban R
Aliment Pharmacol Ther; 2006 Feb; 23(3):409-19. PubMed ID: 16423000
[TBL] [Abstract][Full Text] [Related]
11. Chronic hepatitis B treatment: the cost-effectiveness of interferon compared to lamivudine.
Almeida AM; da Silva AL; Cherchiglia ML; Andrade EI; de Oliveira GL; Acurcio Fde A
Value Health; 2011; 14(5 Suppl 1):S24-8. PubMed ID: 21839893
[TBL] [Abstract][Full Text] [Related]
12. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation.
Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A
Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B.
Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG
Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
Wu B; Shen J; Cheng H
BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan.
Sullivan SD; Veenstra DL; Chen PJ; Chang TT; Chuang WL; Tsai C; Patel K
J Gastroenterol Hepatol; 2007 Sep; 22(9):1494-9. PubMed ID: 17716353
[TBL] [Abstract][Full Text] [Related]
16. HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.
Veenstra DL; Sullivan SD; Lai MY; Lee CM; Tsai CM; Patel KK
Value Health; 2008; 11(2):131-8. PubMed ID: 18380625
[TBL] [Abstract][Full Text] [Related]
17. [Cost-effectiveness of nucleoside/nucleotide analogues in chronic hepatitis B].
Almeida AM; Silva AL; Brandão CM; Cherchiglia ML; Andrade EI; Araújo de Oliveira GL; Carmo RA; Acurcio Fde A
Rev Saude Publica; 2012 Dec; 46(6):942-9. PubMed ID: 23503535
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
Wang G; Liu Y; Qiu P; Zhou SF; Xu L; Wen P; Wen J; Xiao X
Drug Des Devel Ther; 2015; 9():2839-46. PubMed ID: 26082614
[TBL] [Abstract][Full Text] [Related]
19. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
Vassiliadis TG; Giouleme O; Koumerkeridis G; Koumaras H; Tziomalos K; Patsiaoura K; Grammatikos N; Mpoumponaris A; Gkisakis D; Theodoropoulos K; Panderi A; Katsinelos P; Eugenidis N
J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
[TBL] [Abstract][Full Text] [Related]
20. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
